- Home
- DVS vs SIGA Comparison
DVS vs SIGA Comparison
Compare DVS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DVS | SIGA |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 409.7M | 462.6M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | DVS | SIGA |
|---|---|---|
| Price | $4.65 | $6.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 345.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $6.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $4.95 |
| 52 Week High | $5.38 | $9.62 |
Technical Indicators
Market Signals| Indicator | DVS | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 43.82 |
| Support Level | $4.48 | $6.22 |
| Resistance Level | $4.65 | $6.45 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 50.00 | 56.59 |
Price Performance
Historical ComparisonAbout DVS Dolly Varden Silver Corporation
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.